BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Wang DX, Yang X, Lin JZ, Bai Y, Long JY, Yang XB, Seery S, Zhao HT. Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China. World J Gastroenterol 2020; 26(30): 4465-4478 [PMID: 32874058 DOI: 10.3748/wjg.v26.i30.4465]
URL: https://www.wjgnet.com/1007-9327/full/v26/i30/4465.htm
Number Citing Articles
1
Liang Zhang, He Li, TianFu Wang, RuiXin Wang, Long Cheng, Gang Wang. Real-World Study: A Powerful Tool for Malignant Tumor Research in General SurgeryCancers 2022; 14(21): 5408 doi: 10.3390/cancers14215408
2
Huaiyuan Wang, Ge Zhang, Xiaobo Yang, Zhenhui Lu, Haitao Zhao. Lenvatinib plus immune checkpoint inhibitors or locoregional therapy in unresectable hepatocellular carcinoma: Lessons learned and moving forwardsBiochimica et Biophysica Acta (BBA) - Reviews on Cancer 2023; 1878(1): 188841 doi: 10.1016/j.bbcan.2022.188841
3
Lan Zhang, Junhui Sun, Kui Wang, Haitao Zhao, Xijie Zhang, Zhenggang Ren. First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic ReviewCurrent Oncology 2022; 29(10): 7305 doi: 10.3390/curroncol29100575
4
Jincheng Wang, Rui Wu, Jin-yu Sun, Feifei Lei, Huabing Tan, Xiaojie Lu. An overview: Management of patients with advanced hepatocellular carcinomaBioScience Trends 2022; 16(6): 405 doi: 10.5582/bst.2022.01109
5
Lingbo Hu, Yu Zheng, Jiangyin Lin, Xingpeng Shi, Aidong Wang. Comparison of the effects of lenvatinib and sorafenib on survival in patients with advanced hepatocellular carcinoma: A systematic review and meta-analysisClinics and Research in Hepatology and Gastroenterology 2023; 47(1): 102061 doi: 10.1016/j.clinre.2022.102061
6
Bo Hyun Kim, Su Jong Yu, Wonseok Kang, Sung Bum Cho, Soo Young Park, Seung Up Kim, Do Young Kim. Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinomaJournal of Gastroenterology and Hepatology 2022; 37(3): 428 doi: 10.1111/jgh.15727
7
Yuan-Hung Kuo, Sheng-Nan Lu, Yen-Yang Chen, Kwong-Ming Kee, Yi-Hao Yen, Chao-Hung Hung, Tsung-Hui Hu, Chien-Hung Chen, Jing-Houng Wang. Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching AnalysisFrontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.737767
8
Carla Pires Amaro, Michael J. Allen, Jennifer J. Knox, Erica S. Tsang, Howard J. Lim, Richard M. Lee‐Ying, Kelvin W. Chan, Jessica Qian, Brandon M. Meyers, Alia Thawer, Sulaiman M. S. Al‐Saadi, Tina Hsu, Ravi Ramjeesingh, Hatim Karachiwala, Tasnima Abedin, Vincent C. Tam. Dosing, efficacy and safety of lenvatinb in the real‐world treatment of hepatocellular carcinoma: Results from a Canadian databaseLiver Cancer International 2022; 3(3): 119 doi: 10.1002/lci2.59
9
Yuezhi Zhu, Jen Kit Tan, Jo Aan Goon. Cuproptosis- and m6A-Related lncRNAs for Prognosis of Hepatocellular CarcinomaBiology 2023; 12(8): 1101 doi: 10.3390/biology12081101
10
Yi-Nan Ding, Ming Xue, Qiu-Sha Tang, Li-Jun Wang, Hui-Yan Ding, Han Li, Cheng-Cheng Gao, Wei-Ping Yu. Immunotherapy-based novel nanoparticles in the treatment of gastrointestinal cancer: Trends and challengesWorld Journal of Gastroenterology 2022; 28(37): 5403-5419 doi: 10.3748/wjg.v28.i37.5403
11
Andrea R. Mospan, Heather L. Morris, Michael W. Fried. Real‐world evidence in hepatocellular carcinomaLiver International 2021; 41(S1): 61 doi: 10.1111/liv.14864
12
Takeshi Hatanaka, Atsushi Naganuma, Satoru Kakizaki. Lenvatinib for Hepatocellular Carcinoma: A Literature ReviewPharmaceuticals 2021; 14(1): 36 doi: 10.3390/ph14010036
13
Margherita Rimini, Shigeo Shimose, Sara Lonardi, Toshifumi Tada, Gianluca Masi, Hideki Iwamoto, Eleonora Lai, Valentina Burgio, Atsushi Hiraoka, Toru Ishikawa, Caterina Soldà, Tomotake Shirono, Caterina Vivaldi, Koichi Takaguchi, Noritomo Shimada, Giorgio Astara, Hironori Koga, Kazuhiro Nouso, Kouji Joko, Takuji Torimura, Yoichi Hiasa, Francesca Salani, Mario Scartozzi, Stefano Cascinu, Andrea Casadei‐Gardini. Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control studyHepatology Research 2021; 51(12): 1229 doi: 10.1111/hepr.13718
14
Meng Jia, Jiang-Kun Jia, Jian Xu, Huan-Zhou Xue. Feasibility and Tolerability of Lenvatinib, Plus PD-1 Blockades for Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Exploratory StudyCancer Management and Research 2022; : 2625 doi: 10.2147/CMAR.S372125
15
I.G. Rapposelli, S. Shimose, T. Kumada, S. Okamura, A. Hiraoka, G.G. Di Costanzo, F. Marra, E. Tamburini, A. Forgione, F.G. Foschi, M. Silletta, S. Lonardi, G. Masi, M. Scartozzi, M. Nakano, H. Shibata, K. Kawata, A. Pellino, C. Vivaldi, E. Lai, A. Takata, K. Tajiri, H. Toyoda, R. Tortora, C. Campani, M.G. Viola, F. Piscaglia, F. Conti, C.A.M. Fulgenzi, G.L. Frassineti, M.D. Rizzato, F. Salani, G. Astara, T. Torimura, M. Atsukawa, T. Tada, V. Burgio, M. Rimini, S. Cascinu, A. Casadei-Gardini. Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinomaESMO Open 2021; 6(4): 100190 doi: 10.1016/j.esmoop.2021.100190
16
Yuxian Bai, Xichun Hu, Zhenggang Ren, Takashi Hisai, Wataru Yusa, Lidong Weng, Sari Shiba, Takao Takase. A phase I pharmacokinetic study of lenvatinib in Chinese patients with unresectable hepatocellular carcinomaFuture Oncology 2022; 18(22): 2413 doi: 10.2217/fon-2022-0229
17
Bo Liu, Xiao Shang, Jin-Yu Shi, Guo-Zhen Cui, Xi Li, Nan-Ya Wang. Early Alpha-Fetoprotein Response Is Associated With Survival in Patients With HBV-Related Hepatocellular Carcinoma Receiving LenvatinibFrontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.807189
18
Martina Catalano, Andrea Casadei-Gardini, Gianmarco Vannini, Claudia Campani, Fabio Marra, Enrico Mini, Giandomenico Roviello. Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinomaExpert Review of Clinical Pharmacology 2021; 14(11): 1353 doi: 10.1080/17512433.2021.1958674
19
Meng Tao, Jing Han, Juanyi Shi, Hao Liao, Kai Wen, Weidong Wang, Sintim Mui, Huoming Li, Yongcong Yan, Zhiyu Xiao. Application and Resistance Mechanisms of Lenvatinib in Patients with Advanced Hepatocellular CarcinomaJournal of Hepatocellular Carcinoma 2023; : 1069 doi: 10.2147/JHC.S411806
20
Ming‐Hao Xu, Cheng Huang, Mei‐Ling Li, Xiao‐Dong Zhu, Chang‐Jun Tan, Jian Zhou, Jia Fan, Hui‐Chuan Sun, Ying‐Hao Shen. Effectiveness and safety of lenvatinib plus anti‐programmed death‐1 antibodies in patients with hepatocellular carcinoma: A real‐world cohort studyCancer Medicine 2023; 12(8): 9202 doi: 10.1002/cam4.5661
21
Qingqing Li, Tong Su, Xu Zhang, Yanfeng Pan, Shengli Ma, Lu Zhang, Xianqiang Zhang, Xiaojuan Gao. A Real-World Study of Optimal Treatment with Anlotinib First-Line Therapy in Advanced Hepatocellular CarcinomaCancer Management and Research 2022; : 3037 doi: 10.2147/CMAR.S379911
22
Marie Decraecker, Caroline Toulouse, Jean-Frédéric Blanc. Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on LenvatinibCancers 2021; 13(24): 6310 doi: 10.3390/cancers13246310
23
Han Ah Lee, Sunmin Park, Yeon Seok Seo, Won Sup Yoon, In‐Soo Shin, Chai Hong Rim. Surgery versus external beam radiotherapy for hepatocellular carcinoma involving the inferior vena cava or right atrium: A systematic review and meta‐analysisJournal of Hepato-Biliary-Pancreatic Sciences 2021; 28(12): 1031 doi: 10.1002/jhbp.865
24
Han Ah Lee, Chai Hong Rim. Efficacy of Local Treatments for Hepatocellular Carcinoma Involving the Inferior Vena Cava and/or Right AtriumJournal of Hepatocellular Carcinoma 2020; : 435 doi: 10.2147/JHC.S285357
25
Takeshi Hatanaka, Satoru Kakizaki, Tamon Nagashima, Masashi Namikawa, Takashi Ueno, Hiroki Tojima, Daichi Takizawa, Atsushi Naganuma, Hirotaka Arai, Norifumi Harimoto, Ken Shirabe, Toshio Uraoka. Lenvatinib for Hepatocellular Carcinoma Patients with Nonviral Infection Who Were Unlikely to Respond to Immunotherapy: A Retrospective, Comparative StudyOncology 2021; 99(10): 641 doi: 10.1159/000517494